On July 20, 2022, Patrick F. Kelly, M.D., Senior Vice President and Chief Medical Officer, and a named executive officer, of Forma Therapeutics Holdings, Inc. provided notice of his resignation from employment with the Company, effective August 3, 2022 (the Separation Date"). In connection with his resignation, Dr. Kelly and the Company entered into a Transition and General Release Agreement on July 22, 2022 pursuant to which Dr. Kelly (i) will receive compensation equal to his current base salary ($471,215 in the aggregate) over a period of 12 months following the Separation Date and (ii) provided a release of claims against the Company. During the term of the Consulting Agreement, Dr. Kelly's current outstanding unvested equity grants shall continue to vest.

Also on July 20, 2022, Selwyn Vickers, M.D., notified the Company of his intent to resign from the Company's Board of Directors (the Board"), effective July 31, 2022.